SKILLMAN, N.J., Oct. 29 /PRNewswire/ -- ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, today announced that Michael E. Steadman will join ConvaTec as President of the company's Wound Therapeutics Business Unit and Nino Pionati has been appointed as President of the company's Ostomy Care Business Unit.
Previously, the company had announced the formation of four new operating divisions -- Ostomy Care, Wound Therapeutics, Continence and Critical Care and Infusion Devices -- following the acquisition of Copenhagen-based Unomedical in September.
In their new roles, Steadman and Pionati will have global responsibility for their respective major business units, which together account for more than 70 percent of the combined company's $1.7 billion (US) annual sales. In addition, they will focus on developing and driving global business strategy and operational excellence to help the company achieve its stated goal of outperforming the market in its focused businesses.
"As ConvaTec moves forward as a stand-alone company under the ownership of Nordic Capital and Avista Capital Partners, we are poised to accelerate growth both above and below the line," said David Johnson, CEO, ConvaTec. "Our new operational structure, driving strategy from a global level while concentrating our delivery and service strengths within markets, will help us achieve our ultimate goal of leadership in each of our four business areas."
Steadman joins ConvaTec from DFB Pharmaceuticals, Inc. where he was Group President and Chief Operating Officer of DFB Branded Pharmaceuticals. Previously, he served as President of Healthpoint, Ltd., a DFB Unit, creating one of the fastest growing pharmaceutical and biologic wound care companies in the world. As President, Wound Therapeutics, Steadman will become part of the ConvaTec Executive Committee.
Pionati has been with ConvaTec since 1998, and most r
Copyright©2008 PR Newswire.
All rights reserved